Vaccine manufacturing facility
French pharmaceutical company Sanofi Pasteur has unveiled plans to build a new vaccine manufacturing facility in Toronto, Ontario, Canada.
Sanofi will invest more than €350m ($432m) in the state-of-the-art vaccine plant, which is the company’s largest facility-based investment to date.
The project was announced in April 2018 and construction is expected to be completed in 2021. The new facility is expected to commence operations in 2023 and will double the company’s vaccines output.
The new facility will enable Sanofi to support its paediatric and booster vaccines capacity to meet growing demand in the market. It will also strengthen the company’s Canadian operations.
The project is expected to provide up to 1,250 jobs.
Sanofi’s vaccine manufacturing facility will be located at Sanofi Pasteur’s Connaught Campus in North Toronto, which is the company’s headquarters for Canadian vaccine production and research and development (R&D).
Canada was selected as the ideal location for the new facility due to its strong legacy in vaccine R&D.
With a built-up area of 150,000ft², the new plant will feature equipment to manufacture tetanus vaccines and the antigens needed for the treatment of diphtheria. It will also manufacture five-component acellular pertussis (5-acP) antigen, which was researched and developed in Canada.
There is a growing demand for vaccines indicated for the treatment of whooping cough in children and adults. The new vaccine manufacturing facility will enable Sanofi to launch the whooping cough vaccine in more than 30 international markets.
Sanofi’s vaccine manufacturing facility will receive C$70m ($55.5m) from the governments of Canada and Ontario.
A total of C$20m ($15.8m) from the $70m funding will be provided by the federal economic development agency for Southern Ontario (FedDev Ontario) through the Advanced Manufacturing Fund (AMF), a development programme that supports Ontario’s manufacturing sector.
The remaining C$50m ($39.7m) will be provided by the Government of Ontario through the Jobs and Prosperity Fund, which was created to promote R&D activity and finance projects related to pharmaceutical research in the state.
Sanofi has also requested the Economic Development Committee of Ontario to approve a property tax incentive under the Imagination, Manufacturing, Innovation and Technology (IMIT) programme, a business incentive programme that encourages new investment and employment.
Sanofi’s Toronto campus was initially founded as Antitoxin Laboratory in 1914 within the University of Toronto. It was later expanded by opening a pharmaceutical farm in North Toronto in 1917.
The company’s Toronto campus specialises in the development and manufacture of life-saving medicines for the US, Canada and other international markets. Spread across 54 acres, the campus includes office space, R&D labs and various vaccine manufacturing facilities. It employs approximately 1,400 people in industrial and commercial operations, and R&D.
The Toronto site manufactures nine products for serious bacterial infections such as pertussis, diphtheria and tetanus. Vaccines manufactured for these diseases include Pentacel®, Pediacel®, Adacel®, Adacel®-Polio, Quadracel®, Daptacel®, Td Adsorbed, Td Polio Adsorbed, and Tubersol®.
Cytiva opened a new facility for manufacturing Xcellerex XDR bioreactors in Shrewsbury, Massachusetts, US, in December 2020. The new manufacturing…
Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. The expansion will…
Thermo Fisher Scientific is developing a new current good manufacturing practice (cGMP) facility in Carlsbad, California to expand its clinical…
KBI Biopharma is building a new commercial biologics manufacturing facility in the Research Triangle Park (RTP), Durham, in North Carolina,…